Matching articles for "ruxolitinib"
Issue 1749 · March 2, 2026
Drugs for Atopic Dermatitis

Atopic dermatitis (AD), also known as eczema, is frequently associated with other atopic disorders such as allergic rhinitis, asthma, and food allergy. It commonly presents in infancy and early childhood and…

Med Lett Drugs Ther. 2026 Mar 2; 68(1749):33-40 doi:10.58347/tml.2026.1749a
Atopic dermatitis (AD), also known as eczema, is frequently associated with other atopic disorders such as allergic rhinitis, asthma, and food allergy. It commonly presents in infancy and early childhood and has a relapsing course, often improving by adolescence, but sometimes persisting into or first appearing in adulthood or even old age. Guidelines for the treatment of AD have recently been updated.
Issue 1749 · March 2, 2026 Free
Comparison Chart: Topical Nonsteroidal Drugs for Atopic Dermatitis (online only)

View the Comparison Chart: Topical Nonsteroidal Drugs for Atopic Dermatitis

Med Lett Drugs Ther. 2026 Mar 2; 68(1749):e41-2 doi:10.58347/tml.2026.1749d
View the Comparison Chart: Topical Nonsteroidal Drugs for Atopic Dermatitis
Issue 1739 · October 13, 2025
Delgocitinib Cream (Anzupgo) for Chronic Hand Eczema

The FDA has approved a 2% cream formulation of delgocitinib ( Anzupgo – Leo), a Janus kinase (JAK) inhibitor, for treatment of moderate to severe chronic hand eczema (dermatitis) in adults who had an…

Med Lett Drugs Ther. 2025 Oct 13; 67(1739):163-5 doi:10.58347/tml.2025.1739b
The FDA has approved a 2% cream formulation of delgocitinib ( Anzupgo – Leo), a Janus kinase (JAK) inhibitor, for treatment of moderate to severe chronic hand eczema (dermatitis) in adults who had an inadequate response to or are unable to use topical corticosteroids. Delgocitinib is the first drug to be approved in the US for this indication. Ruxolitinib, another JAK inhibitor, is available in a 1.5% cream formulation (Opzelura) for treatment of mild to moderate atopic dermatitis in patients ≥2 years old.
Issue 1723 · March 3, 2025
Tapinarof Cream (Vtama) for Atopic Dermatitis

Tapinarof 1% cream ( Vtama – Dermavant), an aryl hydrocarbon receptor (AhR) agonist, has been approved by the FDA for topical treatment of atopic dermatitis in patients ≥2 years old. Tapinarof is the first…

Med Lett Drugs Ther. 2025 Mar 3; 67(1723):37-8 doi:10.58347/tml.2025.1723c
Tapinarof 1% cream ( Vtama – Dermavant), an aryl hydrocarbon receptor (AhR) agonist, has been approved by the FDA for topical treatment of atopic dermatitis in patients ≥2 years old. Tapinarof is the first AhR agonist to be approved in the US for this indication. It was approved in 2022 for treatment of plaque psoriasis in adults.
Issue 1715 · November 11, 2024
Axatilimab (Niktimvo) for Chronic Graft-Versus-Host Disease (online only)

Axatilimab-csfr ( Niktimvo – Incyte), a colony stimulating factor-1 receptor-blocking antibody, has been approved by the FDA for intravenous treatment of chronic graft-versus-host disease (cGVHD) after…

Med Lett Drugs Ther. 2024 Nov 11; 66(1715):e184-5 doi:10.58347/tml.2024.1715e
Axatilimab-csfr ( Niktimvo – Incyte), a colony stimulating factor-1 receptor-blocking antibody, has been approved by the FDA for intravenous treatment of chronic graft-versus-host disease (cGVHD) after failure of at least 2 lines of systemic therapy in patients weighing ≥40 kg. Corticosteroids are generally the first-line treatment for cGVHD. The oral kinase inhibitors ibrutinib (Imbruvica) , ruxolitinib (Jakafi) , and belumosudil (Rezurock) are also approved for treatment of cGVHD. Extracorporeal photopheresis has been used off-label.
Issue 1711 · September 16, 2024
Roflumilast Cream (Zoryve) for Atopic Dermatitis

The FDA has approved a 0.15% cream formulation of the phosphodiesterase-4 (PDE4) inhibitor roflumilast ( Zoryve – Arcutis) for topical treatment of mild to moderate atopic dermatitis (AD) in patients ≥6…

Med Lett Drugs Ther. 2024 Sep 16; 66(1711):150-1 doi:10.58347/tml.2024.1711b
The FDA has approved a 0.15% cream formulation of the phosphodiesterase-4 (PDE4) inhibitor roflumilast ( Zoryve – Arcutis) for topical treatment of mild to moderate atopic dermatitis (AD) in patients ≥6 years old. Roflumilast is the second PDE4 inhibitor to be approved in the US for treatment of AD; crisaborole (Eucrisa) , which can be used in patients ≥3 months old, was the first. Roflumilast is available as Zoryve in a 0.3% cream for treatment of plaque psoriasis and a 0.3% foam for treatment of seborrheic dermatitis. It is also available in an oral formulation (Daliresp) for treatment of chronic obstructive pulmonary disease.
Issue 1690 · November 27, 2023
Ritlecitinib (Litfulo) for Severe Alopecia Areata

The FDA has approved ritlecitinib ( Litfulo – Pfizer), an oral JAK and TEC kinase family inhibitor, for treatment of severe alopecia areata in patients ≥12 years old. Ritlecitinib is the second oral drug…

Med Lett Drugs Ther. 2023 Nov 27; 65(1690):185-6 doi:10.58347/tml.2023.1690a
The FDA has approved ritlecitinib ( Litfulo – Pfizer), an oral JAK and TEC kinase family inhibitor, for treatment of severe alopecia areata in patients ≥12 years old. Ritlecitinib is the second oral drug to be approved in the US for treatment of severe alopecia areata; baricitinib (Olumiant) , a JAK inhibitor, is approved only for use in adults.
Issue 1660 · October 3, 2022
Ruxolitinib Cream (Opzelura) for Nonsegmental Vitiligo

The 1.5% cream formulation of the Janus kinase (JAK) inhibitor ruxolitinib ( Opzelura – Incyte) has been approved by the FDA for topical treatment of nonsegmental vitiligo (NSV) in patients ≥12 years old.…

Med Lett Drugs Ther. 2022 Oct 3; 64(1660):158-9
The 1.5% cream formulation of the Janus kinase (JAK) inhibitor ruxolitinib ( Opzelura – Incyte) has been approved by the FDA for topical treatment of nonsegmental vitiligo (NSV) in patients ≥12 years old. Opzelura is the first product to be approved by the FDA for this indication. It was previously approved for treatment of atopic dermatitis.
Issue 1658 · September 5, 2022
Baricitinib (Olumiant) for Severe Alopecia Areata

The oral Janus kinase (JAK) inhibitor baricitinib ( Olumiant – Lilly), which was previously approved by the FDA for treatment of moderately to severely active rheumatoid arthritis and treatment of COVID-19…

Med Lett Drugs Ther. 2022 Sep 5; 64(1658):139-41
The oral Janus kinase (JAK) inhibitor baricitinib ( Olumiant – Lilly), which was previously approved by the FDA for treatment of moderately to severely active rheumatoid arthritis and treatment of COVID-19 in certain hospitalized adults, has now been approved for treatment of severe alopecia areata in adults. Baricitinib is the first systemic treatment to be approved in the US for this indication.
Issue 1642 · January 24, 2022
Ruxolitinib (Opzelura) for Atopic Dermatitis

The FDA has approved a 1.5% topical cream formulation of the Janus kinase (JAK) inhibitor ruxolitinib ( Opzelura – Incyte) for short-term, non-continuous chronic treatment of mild to moderate atopic…

Med Lett Drugs Ther. 2022 Jan 24; 64(1642):12-3
The FDA has approved a 1.5% topical cream formulation of the Janus kinase (JAK) inhibitor ruxolitinib ( Opzelura – Incyte) for short-term, non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised patients ≥12 years old whose disease has not been adequately controlled with other topical prescription drugs. Ruxolitinib is the first JAK inhibitor to be approved for topical use and the first to be approved in the US for treatment of AD. An oral formulation of ruxolitinib (Jakafi) is approved for treatment of myelofibrosis, polycythemia vera, and graft-versus-host disease.
Issue 1595 · April 6, 2020 Free
Table: Treatments Considered for COVID-19 (Archived) (online only)

View the Table: Treatments Considered for COVID-19

Med Lett Drugs Ther. 2020 Apr 6; 62(1595):e1-289
View the Table: Treatments Considered for COVID-19
Issue 1387 · April 2, 2012
Ruxolitinib (Jakafi) for Myelofibrosis

The FDA has approved ruxolitinib ( Jakafi – Incyte), a janus-associated kinase (JAK) inhibitor, for treatment of myelofibrosis. Jakafi is the first JAK inhibitor to be approved for any indication and the…

Med Lett Drugs Ther. 2012 Apr 2; 54(1387):27-8
The FDA has approved ruxolitinib ( Jakafi – Incyte), a janus-associated kinase (JAK) inhibitor, for treatment of myelofibrosis. Jakafi is the first JAK inhibitor to be approved for any indication and the only drug approved for treatment of myelofibrosis.